May 13th 2024
In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Aldape Takes on Role as Chief of the Laboratory of Pathology at NCI
February 21st 2018Kenneth Aldape, MD, has joined the National Cancer Institute’s Center for Cancer Research as chief of the Laboratory of Pathology, an integral component of the research and clinical community at the National Institutes of Health.<br />
Read More
DNX-2401 Demonstrates Promising Survival Benefit for Patients With Glioma
February 16th 2018According to results of a phase I study recently published in <em>Journal of Clinical Oncology</em>, treatment with the investigational agent DNX-2401 resulted in 20% of patients with recurrent malignant glioma surviving more than 3 years from the time of treatment.
Read More
Bevacizumab/Lomustine Combinations Falls Short in Phase III Glioblastoma Trial
January 31st 2018Treatment with lomustine plus bevacizumab provided a slightly improved progression-free survival, but did not demonstrate an overall survival advantage over treatment with lomustine alone in patients with progressive glioblastoma, according to results of a randomized phase III trial published in the<em> New England Journal of Medicine</em>.
Read More
A phase III clinical trial of VAL-083, a first-in-class small molecule chemotherapy agent, has opened for patients with glioblastoma multiforme whose disease has progressed during or after standard treatment with chemoradiation, according to a news release from Atlantic Health System.
Read More
Survival Improved with Tumor-Treating Fields in Glioblastoma
January 23rd 2018Progression-free survival and overall survival were improved for patients with glioblastoma by adding tumor-treating fields to temozolomide (Temodar), according to a final analysis of results from the EF-14 trial.
Read More
A Look Back at FDA News in the Month of December
January 3rd 2018The FDA closed out the year by approving several new agents last month, including bevacizumab for glioblastoma, cabozantinib for renal cell carcinoma, nivolumab for melanoma, bosutinib for chronic myeloid leukemia, and pertuzumab for HER2+ breast cancer. In addition, several agents were granted a priority review designation. Here is a look back at all the FDA activity that took place in December.
Read More
Study Evaluating Several Drugs in Parallel for Newly Diagnosed Glioblastoma
December 20th 2017Several agents are being investigated for the treatment of patients with glioblastoma in an ongoing phase II clinical trial. Known as the INdividualized Screening Trial of Innovative Glioblastoma Therapy, the study will randomize patients to 1 of 4 arms—either the control arm of standard-of-care agent temozolomide, or 1 of 3 experimental arms.
Read More
Oncolytic Virus Induces Durable Responses in Recurrent Gliomas
December 14th 2017The novel oncolytic virus Toca 511 (vocimagene amiretrorepvec) and Toca FC (extended-release 5-fluorocytosine [5-FC]) induced durable responses in patients with recurrent glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA), for a median duration of response of 35.1+ months, according to findings from a phase I study presented during the 2017 AACRNCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. In a pooled analysis of 3 phase I studies, the virus also proved to be well tolerated with fewer any-grade adverse events (AEs) than with standard chemotherapy.1
Read More
DFS Maintained in HR+ Breast Cancer With Fewer Years of AI Therapy
December 8th 2017Disease-free survival is maintained in women with postmenopausal hormone receptor-positive breast cancer treated with aromatase inhibitors, even when the treatment is only given for 2 years in comparison with the standard 5 years of additional aromatase inhibitor therapy, according to findings from the phase III ABCSG-16 trial presented at the 2017 San Antonio Breast Cancer Symposium.
Read More
Bevacizumab Granted Full FDA Approval for Glioblastoma
December 7th 2017After previously receiving an accelerated approval, bevacizumab (Avastin) has been granted a full approval by the FDA for the treatment of adult patients with glioblastoma that progressed following prior therapy, according to Genentech, the manufacturer of the VEGF inhibitor.
Read More
ABP-215, First Biosimilar for Cancer Treatment, Approved by FDA
September 15th 2017Today, ABP-215, a biosimilar for bevacizumab developed by Amgen and Allergan, received FDA approval for the treatment of several different cancer types, making it the first biosimilar approved for the treatment of cancer.
Read More
Engineering Chimeric Antigen Receptor T Cells to Treat Glioblastoma
August 18th 2017The authors share their experience with EGFRvIII-specific chimeric antigen receptors, which they hope will contribute to the growing body of research committed to discovering a novel therapy for glioblastoma.
Read More
Four Neuro-Oncology Experts to Lead New Glioblastoma Research Center at NewYork-Presbyterian
May 25th 2017NewYork-Presbyterian has established the William Rhodes and Louise Tilzer-Rhodes Center for Glioblastoma, to be led by physicians from Columbia University Medical Center and Weill Cornell Medicine.
Read More
Exploring Vaccination in Low-Grade Glioma With the Aim of Preventing High-Grade Transformation
May 17th 2017Hideho Okada, MD, PhD, director, Brain Tumor Immunotherapy Center, professor of Neurological Surgery, University of California, San Francisco, discusses a study exploring vaccination in low-grade glioma aiming at prevention of high-grade transformation.
Watch
Exploiting DNA Repair Deficiency in IDH-Mutant Brain Tumors Likely an Improved Treatment Strategy
April 6th 2017Mutations in isocitrate dehydrogenase 1 and 2 (<em>IDH1/2</em>) are not the mutations commonly found in cancer cells, according to a presentation from the 2017 AACR Annual Meeting.
Read More
TTFields Significantly Improve Survival in GBM
April 5th 2017A landmark analysis of findings from the EF-14 trial testing the efficacy and safety of tumor treating fields for the treatment of patients with glioblastoma multiforme has found that the risk of death was reduced by 37% and overall survival was extended by a median of 5 months with the use of the device.
Read More
New Study Aims to Extend TTFields Beyond Grade IV Brain Cancer Domain
January 17th 2017The use of tumor treating fields as a treatment for patients with brain tumors has, thus far, largely been focused on in glioblastoma, but an upcoming trial aims to expand the use of the device to the grade III patient population, says Daniel O’Connell, MD.
Read More
The Impact of WHO's Tumor Reclassifications on Brain Cancer Care
January 13th 2017Arie Perry, MD, chief of neuropathology at UCSF in San Francisco, California, discusses what oncologists should be aware of when diagnosing patients after these reclassifications, how it could change pathology, as well as a discussion on hereditary tumors.
Read More
Metabolic Pathways May Provide Opportunity for Novel Therapeutic Targeting in Neuro-Oncology
December 21st 2016In an interview with <em>Targeted Oncology</em>, Howard Fine discusses the reason for renewed interested in metabolic targets, the effect it has had on treatment of gliomas, and what he sees on the horizon for neuro-oncology in this area.<br />
Read More
No Clinical Benefit From Added Onartuzumab Demonstrated in Glioblastoma Study
December 21st 2016Treatment with onartuzumab did not provide any additional clinical benefit when added to bevacizumab (Avastin) in the treatment of patients with recurrent glioblastoma multiforme (GBM), according to a study recently published in the <em>Journal of Clinical Oncology</em>.
Read More
Entrectinib Will Likely Play an Increasing Role in Treating Brain Tumors, Other Cancers, Expert Says
November 30th 2016Researchers are currently investigating the use of tropomyosin receptor kinase (TRK) inhibitor entrectinib (RXDX-101) to treat patients with relapsed or refractory solid tumors or primary tumors of the central nervous system.
Read More